| Issue |
Med Sci (Paris)
Volume 41, Number 6-7, Juin-Juillet 2025
Chroniques génomiques
|
|
|---|---|---|
| Page(s) | 611 - 614 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/2025097 | |
| Published online | 07 July 2025 | |
Séquençage de l’ADN
La fin d’un quasi-monopole
DNA sequencing: the end of a near-monopoly
Biologiste, généticien et immunologiste, Président d’Aprogène (Association pour la promotion de la Génomique), Marseille, France
Abstract
For the last decade, the field of DNA sequencing has been dominated by a single company, Illumina, with very limited competition. However, a new method with superior performance and lower cost has recently been announced by Roche, a major pharmaceutical and diagnostics company, and promises to have a large impact, especially (but not exclusively) for medical applications.
© 2025 médecine/sciences – Inserm
Article publié sous les conditions définies par la licence Creative Commons Attribution License CC-BY (https://creativecommons.org/licenses/by/4.0), qui autorise sans restrictions l’utilisation, la diffusion, et la reproduction sur quelque support que ce soit, sous réserve de citation correcte de la publication originale.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.